GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytokinetics Inc (NAS:CYTK) » Definitions » Cyclically Adjusted PS Ratio

Cytokinetics (Cytokinetics) Cyclically Adjusted PS Ratio : 56.87 (As of May. 15, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Cytokinetics Cyclically Adjusted PS Ratio?

As of today (2024-05-15), Cytokinetics's current share price is $59.715. Cytokinetics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $1.05. Cytokinetics's Cyclically Adjusted PS Ratio for today is 56.87.

The historical rank and industry rank for Cytokinetics's Cyclically Adjusted PS Ratio or its related term are showing as below:

CYTK' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.01   Med: 6.77   Max: 85.99
Current: 56.34

During the past years, Cytokinetics's highest Cyclically Adjusted PS Ratio was 85.99. The lowest was 1.01. And the median was 6.77.

CYTK's Cyclically Adjusted PS Ratio is ranked worse than
92.98% of 513 companies
in the Biotechnology industry
Industry Median: 5.58 vs CYTK: 56.34

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Cytokinetics's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.008. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.05 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Cytokinetics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Cytokinetics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytokinetics Cyclically Adjusted PS Ratio Chart

Cytokinetics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.12 22.03 43.16 38.90 76.95

Cytokinetics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.37 27.03 24.60 76.95 66.54

Competitive Comparison of Cytokinetics's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Cytokinetics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytokinetics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytokinetics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Cytokinetics's Cyclically Adjusted PS Ratio falls into.



Cytokinetics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Cytokinetics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=59.715/1.05
=56.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cytokinetics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Cytokinetics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.008/129.4194*129.4194
=0.008

Current CPI (Mar. 2024) = 129.4194.

Cytokinetics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.214 100.560 0.275
201409 0.257 100.428 0.331
201412 0.592 99.070 0.773
201503 0.114 99.621 0.148
201506 0.169 100.684 0.217
201509 0.205 100.392 0.264
201512 0.250 99.792 0.324
201603 0.213 100.470 0.274
201606 0.146 101.688 0.186
201609 1.366 101.861 1.736
201612 0.762 101.863 0.968
201703 0.100 102.862 0.126
201706 0.063 103.349 0.079
201709 0.115 104.136 0.143
201712 0.000 104.011 0.000
201803 0.097 105.290 0.119
201806 0.114 106.317 0.139
201809 0.195 106.507 0.237
201812 0.171 105.998 0.209
201903 0.154 107.251 0.186
201906 0.124 108.070 0.148
201909 0.103 108.329 0.123
201912 0.088 108.420 0.105
202003 0.065 108.902 0.077
202006 0.060 108.767 0.071
202009 0.611 109.815 0.720
202012 0.095 109.897 0.112
202103 0.092 111.754 0.107
202106 0.040 114.631 0.045
202109 0.068 115.734 0.076
202112 0.661 117.630 0.727
202203 0.014 121.301 0.015
202206 1.038 125.017 1.075
202209 0.027 125.227 0.028
202212 0.021 125.222 0.022
202303 0.048 127.348 0.049
202306 0.009 128.729 0.009
202309 0.004 129.860 0.004
202312 0.017 129.419 0.017
202403 0.008 129.419 0.008

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cytokinetics  (NAS:CYTK) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Cytokinetics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Cytokinetics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytokinetics (Cytokinetics) Business Description

Industry
Traded in Other Exchanges
Address
350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Executives
Robert I Blum officer: EVP, Corp. Development & CBO 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John T Henderson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Fady Ibraham Malik officer: SVP Research & Early Dev 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Wendall Wierenga director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Muna Bhanji director C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Robert Wong officer: VP, Chief Accounting Officer 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Ching Jaw officer: SVP Finance & CFO 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Sandford D Smith director C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
B Lynne Parshall director 2855 GAZELLE COURT, CARLSBAD CA 92010
Santo J Costa director
Kaye Edward M. Md director 3450 MONTE VILLA PARKWAY, BOTHELL WA 98011
Robert Arthur Harrington director C/O CYTOKINETICS, INCORPORATED, 350 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Mark A Schlossberg officer: SVP - Legal & General Counsel C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
David Cragg officer: V.P., Human Resources 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
L Patrick Gage director C/O NEOSE TECHNOLOGIES, 102 WITMER RD, HORSHAM PA 19044